J.P.,
I am not sure that I agree with your premise. First - they have had long periods with no news - certainly have not had a "PR every week - or month" , not by a long shot ... more news recently, that is true. In fact, in the early days, one of the major criticisms of this company by the shareholders, was they were not promoting themselves enough.
The only thing that will move this stock significantly, is the approval of one of their 2 drugs. Pennsaid, the arthritis drug, is IMHO likely to be approved within the next few months (6 at the outside) - at least in Canada. They passed a significant hurdle with the FDA recently - that's positive.
The reality ... drug approvals take a long time ... one must be patient. And of course, nothing is guaranteed - but as of now, things look good for this junior biotech company.
MB |
